SAB’s therapeutic candidate, SAB-185, is a new immunotherapy generated from the company’s proprietary technology, the DiversitAb™ platform, to produce fully human polyclonal antibodies that target ...
FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody ...
SAB BIO to Host Webinar Discussing Topline Results from Phase 1 Trial of SAB-142 for Type 1 Diabetes
SAB BIO will host a webinar on January 28, 2025, to discuss Phase 1 trial data for its T1D therapy, SAB-142. SAB BIO, a clinical-stage biopharmaceutical company, announced it will host a webinar on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results